1383572-19-7

1383572-19-7 structure

Name: Cabazitaxel-d9
Chemical Name: Cabazitaxel-d9
CAS Number: 1383572-19-7
Molecular Formula: C₄₅H₄₈D₉NO₁₄
Molecular Weight: 844.99
Catalog: Signaling Pathways Autophagy Autophagy
Create Date: 2021-06-18 18:06:47
Modify Date: 2024-01-10 16:50:29
Cabazitaxel-d9 is deuterium labeled Cabazitaxel. Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

Name	Cabazitaxel-d9
Synonyms	Benzenepropanoic acid, β-[[[[1,1-di(methyl-d3)ethyl-2,2,2-d3]oxy]carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12 ; a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- Cabazitaxel-d9 (2α,5β,7β,10β,13α)-4-Acetoxy-1-hydroxy-13-({(2R,3S)-2-hydroxy-3-[({[2-(2H3)methyl(2H6)-2-propanyl]oxy}carbonyl)amino]-3-phenylpropanoyl}oxy)-7,10-dimethoxy-9-oxo-5,20-epoxytax -11-en-2-yl benzoate

Description	Cabazitaxel-d9 is deuterium labeled Cabazitaxel. Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29. [3]. Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond). 2017 Sep;12(17):2083-2095.